Skip to main content

Table 1 Patients’ baseline characteristics

From: Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia

Characteristic

Risankizumab

(n = 30)

Adalimumab

(n = 40)

p-value

Total

Gender

Male, n (%)

23(76.67)

22(55.00)

0.0612

45(64.29)

Female, n (%)

7(23.33)

18(45.00)

25(35.71)

Age (yrs.), mean ± SD

39.43 ± 15.77

32.83 ± 13.12

0.0601

35.66 ± 14.58

Duration of illness (yrs.), mean ± SD

6.95 ± 7.97

10.50 ± 9.47

0.2274

9.13 ± 8.19

Duration of therapy (months), mean ± SD

11.12 ± 5.53

26.4 ± 18.66

< 0.0001

19.85 ± 16.37

Weight (KG), mean ± SD

93.53 ± 32.63

80.67 ± 23.20

0.0719

86.18 ± 28.16

Height (cm), mean ± SD

168.13 ± 10.02

165.91 ± 9.51

0.3556

166.85 ± 9.72

Body Surface Area (BSA), mean ± SD

22.71 ± 24.43

23.62 ± 23.59

0.8842

23.28 ± 23.72

PASI score, mean ± SD

24.78 ± 20.39

17.91 ± 12.65

0.1109

20.86 ± 16.65

Hypertension, n (%)

5(16.67)

4(10.00)

0.4831

9(12.86)

Diabetes, n (%)

5(16.67)

6(15.00)

1.00

11(15.71)

Asthma, n (%)

0(0.0)

2(5.00)

0.5031

2(2.86)

Cardiovascular disease (CVD), n (%)

2(6.67)

0(0.0)

0.1801

2(2.86)

Dyslipidemia, n (%)

7(23.33)

7(17.50)

0.5460

14(20.00)

Number of comorbidities, n (%)

1.13 ± 1.74

0.68 ± 1.16

0.2173

0.87 ± 1.44